The updated safety profile in JO25567 was largely consistent with the known safety profiles of both erlotinib and bevacizumab in a population with non-small-cell lung cancer (NSCLC).

Adverse events observed more frequently in the erlotinib plus bevacizumab (EB) arm than in the erlotinib alone (E) arm included hypertension, proteinuria, bleeding events, and skin and nail disorders. These adverse events could be monitored, easily detected, and well managed in most cases.

Although EB led to higher rates of bevacizumab discontinuation than previously reported (in the context of prolonged drug exposure), these were not early discontinuations and therefore did not prevent patients from deriving full benefit from treatment.